AVADEL PHARMACEUTICALS PLC (AVDL)
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
Address
BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
DUBLIN, L2 15
Founded
2015
Number of Employees
154
Website
http://www.avadel.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | $19 | $28 | - | - | - | - | - | - | $23 |
| Average Price | - | - | - | $10.67 | $8.40 | - | - | - | - | - | - | $9.20 |
| # Shares Purchased | - | - | - | 1,795 | 3,291 | - | - | - | - | - | - | 2,543 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | 21.9% | 54.8% | - | - | - | - | - | - | 41.3% |
| S&P 500 Return to Date | - | - | - | 129.7% | 104.9% | - | - | - | - | - | - | 117.3% |
| Excess Total Return | - | - | - | -107.8% | -50.1% | - | - | - | - | - | - | -76.0% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | 45% | 60% | - | - | - | - | - | - | 67% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at AVDL make a trade.
Creating a free account takes less than one minute